Abstract
The efficacy of lofexidine/naloxone was compared with lofexidine/placebo in a double-blind, randomized, placebo-controlled trial in 89 opiate-dependent patients. There were no significant differences between the two groups in the proportion of patients completing detoxification or in the length of stay. Patients in the active naloxone group demonstrated gradual reductions in levels of withdrawal and craving over the detoxification period. At completion of detoxification, patients who received naloxone maintained a level of withdrawal consistently lower than that in the placebo group; however, naloxone did not substantially accelerate the resolution of the withdrawal syndrome. Implications for future research are discussed.
Original language | English |
---|---|
Pages (from-to) | 295 - 305 |
Number of pages | 11 |
Journal | American Journal on Addictions |
Volume | 12 |
Issue number | 4 |
DOIs | |
Publication status | Published - Jul 2003 |